Drug intelligence / Profile preview

Treataprost

Development stage: Preclinical
Lead developer: Grand Medical Group
Administration: Oral

Overview

Treataprost is a herbal therapeutic agent developed by Grand Medical Group, primarily investigated for the treatment of urological conditions such as chronic prostatitis and benign prostatic hyperplasia (BPH). It is currently in the preclinical stage of development, with research focusing on its efficacy in rat models of prostatic inflammation. The formulation is part of Grand Medical Group's R&D portfolio alongside other herbal-based agents like Tutukon and pari-flo. Preclinical studies have demonstrated its ability to modulate inflammatory responses and improve morphological changes in prostatic tissue.

Brand names: Treataprost
Other names: Treataprost

Beyond the preview

Go deeper on Treataprost.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Treataprost.

Explore the full profile